life science outsourcing j-pac medical

[Image courtesy of LSO/J-Pac Medical]

Life Science Outsourcing announced that it acquired manufacturing, packaging and sterilization outsourcing partner J-Pac Medical.

J-Pac offers outsourcing to medical device and diagnostic companies. Headquartered in Somersworth, New Hampshire, it brings more than 35 years of experience providing solutions for OEMs.

According to a news release, the company also has experience in complex thermoplastic devices, packaging and in-house tooling capabilities. This allows it to manufacture anatomically correct, class III implantable textile assemblies, lab-on-chip reagent blisters and complicated thermoformed packaging. It has an established a leading presence in the implantable medical textiles and diagnostics end markets.

J-Pac Medical operates a 60,000-square-foot, ISO 13485-certified, FDA-registered facility with cleanroom capabilities in New Hampshire. It also has strong supplier relationships in Costa Rica.

“J-Pac Medical stood out as a unique and attractive business that aligned perfectly with LSO’s strategic and commercial objectives,” said LSO CEO John Nino. “The company’s capabilities in reagent blister packaging, thermoforming and biomaterials will be additive to LSO’s existing customer base. J-Pac Medical’s assembly, packaging and sterilization capabilities are complimentary to LSO and both will be strengthened by this truly synergistic alliance.”

PPC, the parent company of LSO, acquired it in January 2021. PPC Operating Partner John Morgan said the combination allows the company to provide a wider array of services to customers across an even broader geographic footprint.

“J-Pac Medical’s technical know-how and production experience around reagent blister packaging in the molecular diagnostics end-market represents an exciting growth opportunity given trends in point-of-care diagnostics, specifically as it relates to microfluidics and lab-on-a-chip applications,” said Jeff Barrett, president of J-Pac’s diagnostics division. Our partnership with LSO broadens our reach within the life sciences and diagnostics end-markets we are targeting.”